カテゴリ： GlobalData, スイス, 企業調査

F. Hoffmann-La Roche Ltd (ROG)：医療機器：M&Aディール及び事業提携情報

◆英語タイトル：F. Hoffmann-La Roche Ltd (ROG) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA904C7453
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：228
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：スイス
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company, which develops drugs and diagnostics that improve the standard of care in major disease areas. It provides pharmaceuticals in cancer, neuroscience, infection, immunology, ophthalmology, cardiovascular and metabolism, hematology, neurology and respiratory disease areas. The company also provides in vitro diagnostics and tissue-based cancer diagnostics, besides diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose and treat diseases. The company offers its products and services to hospitals, commercial diagnostic laboratories, healthcare professionals, researchers and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries all over the world. Roche is headquartered in Basel, Switzerland.

F. Hoffmann-La Roche Ltd (ROG) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 9
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 11
F. Hoffmann-La Roche Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 12
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 13
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 14
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 15
F. Hoffmann-La Roche Ltd, Medical Equipment, Deal Details 25
Asset Purchase 25
Roche Latvija to Acquire Distribution Business from Medilink 25
Roche Diagnostics to Acquire Tissue Dissection Technology from AvanSci Bio 26
Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 27
Venture Financing 28
Care Innovations Raises Funds through Series B Venture Financing 28
Syapse Raises USD30 Million in Series D Financing 29
Viewics Raises Additional USD10.5 Million in Series B Venture Financing 31
Omicia Raises USD23 Million in Series B Financing Round 32
Cota Raises Funds through Venture Financing 33
Purigen Biosystems Raises USD18.2 Million in Series A Financing 34
Flatiron Health Raises USD175 Million in Series C Financing 35
mySugr Raises USD4.8 Million in Venture Financing 37
Curetis Raises USD18 Million in Extended Series B Venture Financing 38
GeneWeave Biosciences Raises USD12 Million in Series B Venture Financing 40
Flatiron Health Raises US$130 Million In Series B Financing 41
Curetis Raises US$16.3 Million In Series B Financing 43
MacuLogix Raises US$3.6 Million In Series A Financing 45
Flatiron Health Raises US$8 Million In Series A Financing 46
NexDx Raises US$5.5 Million In Series B Financing 48
Foundation Medicine Secures USD42.5 Million In Series B Financing 49
GeneWeave Raises US$12 Million In Series A Financing Round 51
GeneWeave Biosciences Raises USD12 Million in Venrture Financing 52
Aria Diagnostics Secures US$52.7 Million In Series C Venture Financing 53
Ariosa Diagnostics Secures USD52.7 Million in Series C Funding Round 54
Partnerships 55
Genentech Enters into Licensing Agreement with Vital Art and Science 55
Roche Enters into Licensing Agreement with Becton Dickinson 56
Ariosa Diagnostics Enters into Licensing Agreement with Labs 57
Foundation Medicine Enters into Licensing Agreement with WuXi PharmaTech 58
Roche Enters Into Licensing Agreement With Sysmex Inostics For emPCR Patent Portfolio 59
Thermo Fisher Scientific Extends Licensing Agreement With Roche For Procalcitonin Test 60
Ventana Medical Systems Enters Into Licensing Agreement With Biocare Medical 61
Ventana Medical Enters Into Licensing Agreement With German Cancer Research Center And University Hospital Heidelberg For BRAF V600E 62
Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker 63
NexDx Enters Into Licensing Agreement With University of California For Epigenetic Biomarkers 64
Roche Enters Into Licensing Agreement With Life Technologies For PCR Technology 65
Ventana Medical Systems Enters Into Licensing Agreement With Cell Signaling Technology 66
Roche Enters into Development Agreement with Novo Nordisk 67
Roche Enters into Partnership Agreement with Care Innovations 68
Five Prime Therapeutics Enters into Partnership with Roche 69
Foundation Medicine Enters into Partnership with Merck 70
Foundation Medicine, Roche and DIAN Diagnostics Enter into Partnership 71
Emulate Enters into Agreement with Roche 72
BioPorto Enters into Distribution Agreement with Roche Diagnostics 73
Syapse Enters into Agreement with Roche 74
Roche Enters into Partnership with GE Healthcare 75
Inotrem Enters into Research Agreement with Roche Diagnostics 76
Mimetas and Roche Jointly Develops Gut-On-A-Chip Technology 77
Roche Enters into Agreement with Accenture 78
Senseonics Holdings Enters into Agreement with TypeZero and Roche Diabetes 79
Loxo Oncology Enters into Agreement with Ventana Medical Systems 80
Roche Diabetes Care Enters into Agreement with Medtronic 81
Good Start Genetics Enters into Marketing Agreement with Roche Diagnostics 82
Berkeley Lights Enters into Agreement with F. Hoffmann-La Roche 83
Roche Enters into Agreement with BARDA 84
Horizon Discovery Group Enters into Co-Development Agreement with Ventana Medical Systems 85
Foundation Medicine Enters into Agreement with AstraZeneca 86
Senseonics Amends its Distribution Agreement with F. Hoffmann-La Roche 87
Flatiron Health Partners with Amgen 88
Flatiron Health Partners with Celgene 89
Cellnovo Enters into Agreement with Roche Diagnostics 90
Blueprint Medicines Enters into Co-Development Agreement with Ventana Medical Systems 91
Foundation Medicine Enters into Agreement with Mirati Therapeutics 92
IMS Health Enters into Agreement with Foundation Medicine 93
Halozyme Therapeutics Enters into Co-Development Agreement with Ventana Medical Systems for Cancer Treatment 94
Varian Medical Systems Enters into Co-Development Agreement with Flatiron Health 95
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 96
Molecular Devices Enters into Co-Development Agreement with Roche Diagnostics 97
Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 98
AstraZeneca Enters into Co-Development Agreement with Roche 99
Advanced Biological Labs Extends Co-Promotion Agreement with Roche Diagnostics 100
Bioprocessing Tech Institute Enters Into Agreement with Roche to Develop Cancer Therapeutics 101
Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 102
AUT University Forms Joint Venture with Roche Diagnostics 103
Ventana Medical Enters into Co-Development Agreement with MedImmune 104
Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 105
Foundation Medicine Extends Co-Development Agreement With Clovis Oncology 106
Ventana Extends Co-Development Agreement With Bayer Pharma 107
Ventana Medical Systems Enters Into Co-Development Agreement With Incyte For Companion Diagnostic Tests 108
Ventana Medical Systems Enters Into Agreement With Boehringer Ingelheim For Companion Diagnostic Tests 109
Ariosa Diagnostics Enters Into Agreement With Fleury For Harmony Prenatal Test 110
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 111
Advanced Biological Labs And Roche Diagnostics Enter Into Agreement To Promote Sequencing, Genotyping And Drug Resistance Products 112
Ascendis Pharma Enters Into Collaboration Agreement with Genentech 113
Ventana Medical Systems And TGen Enter Into Agreement To Develop Cancer Diagnostic Markers 114
Ventana Medical And Barco Enter Into Agreement For Digital Pathology Imaging Platform 115
Foundation Medicine Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 116
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 117
Roche Enters Into Co-Development Agreement With BioLamina For Cell Culture Systems 118
Ariosa Diagnostics Enters Into Distribution Agreement With The Doctors Laboratory For Harmony Prenatal Test 119
Epizyme, Eisai And Roche Enter Into Co-Development Agreement For Companion Diagnostic Test 120
Roche Enters Into Co-Development Agreement With Precision System Science For PCR Instrument 121
NCM USA Enters Into Co-Development Agreement With Genentech For Clinical Imaging Agents 122
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 123
Genia Technologies Enters Into Co-Development Agreement With Columbia University And Harvard University 124
Foundation Medicine Enters Into Co-Development Agreement With Clovis Oncology 125
Foundation Medicine Extends Co-Development Agreement With Novartis 126
Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 127
Sysmex Extends Distribution Agreement With Roche 128
Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems 129
Roche Enters Into Co-Development Agreement With Technoclone 131
Ventana Medical Systems Enters Into Co-Development Agreement With Bayer Pharma 132
Ventana Medical Systems Enters Into Co-Development Agreement With Pfizer 133
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 134
AEterna Zentaris Enters Into Co-Development Agreement With Ventana Medical Systems 135
Syndax Pharma Enters Into Co-Development Agreement With Ventana Medical Systems 136
Abcam Enters into Licensing Agreement with Roche 137
Sonic Healthcare Enters into Licensing Agreement with Ariosa Diagnostics 138
Roche Enters into Licensing Agreement with Dalcor Pharma 139
Equity Offering 140
Ignyta Prices Public Offering of Shares for USD160 Million 140
Senseonics Holdings Prices Private Placement of Shares for USD41 Million 142
Foundation Medicine Raises USD250 Million in Private Placement of Shares 144
Ariosa Diagnostics Withdraws IPO 145
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 146
Foundation Medicine Completes IPO Of Shares For US$122 Million 147
Debt Offering 149
Roche Raises USD750 Million in Public Offering of 3.25% Bonds Due 2023 149
Roche Raises USD650 Million in Public Offering of 3.625% Bonds Due 2028 150
Roche Prices Public Offering of Bonds Due 2020 for USD600 Million 151
Roche Prices Public Offering of 0.875% Bonds Due 2025 for USD1.14 Billion 152
Roche Plans to Raise USD850 Million in Public Offering of Notes 153
Roche Plans to Raise USD500 Million in Public Offering of Bonds 154
Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2021 155
Roche Plans to Raise USD1.5 Billion in Public Offering of Bonds 156
Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2024 157
Roche Plans to Raise USD300 Million in Public Offering of Bonds 158
Asset Transactions 159
Roche Rumored To Sell Its Diabetes Device Unit 159
SynenTec To Acquire Cellavista Systems Business From Roche 160
Acquisition 161
Roche to Acquire Remaining Stake in Foundation Medicine for USD2.4 Billion 161
Roche Acquires Flatiron Health for USD1.9 Billion 162
Roche Acquires Ignyta for USD1.7 Billion 163
Roche Acquires mySugr for USD73.1 Million 165
Roche Acquires ForSight VISION4 from ForSight Labs 166
Roche Acquires GeneWEAVE BioSciences for USD350 Million 167
Roche Acquires CAPP Medical 168
Roche Acquires Signature Diagnostics 169
Roche Acquires Ariosa Diagnostics 170
Roche Acquires Bina Technologies 171
F. Hoffmann-La Roche Completes Acquisition of Iquum for USD450 Million 172
Roche Diagnostics Acquires Genia for up to USD350 Million 173
Flatiron Health To Acquire Altos Solutions, Electronic Medical Records Company 174
Fluidigm Completes Acquisition Of DVS Sciences For US$207.5 Million 175
Roche Rumored to Acquire BioMarin Pharma for USD13.5 Billion 177
Roche Acquires Constitution Medical For US$220 Million 178
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 179
Roche Completes Acquisition Of Verum Diagnostica For US$15 Million 181
F. Hoffmann-La Roche Ltd – Key Competitors 182
F. Hoffmann-La Roche Ltd – Key Employees 183
F. Hoffmann-La Roche Ltd – Locations And Subsidiaries 184
Head Office 184
Other Locations & Subsidiaries 184
Recent Developments 196
Strategy And Business Planning 196
Nov 22, 2017: Roche expands its Kaiseraugst site and opens new IT innovation centre 196
Financial Announcements 197
Jul 26, 2018: Roche reports very strong performance in the first half of 2018 197
Feb 01, 2018: Roche reports good results in 2017 200
Oct 19, 2017: Roche reports strong sales growth in the first nine months of 2017 201
Jul 27, 2017: Roche reports strong performance in the first half of 2017 205
Apr 27, 2017: Roche reports a good start in 2017 207
Feb 01, 2017: Roche reports good results in 2016 209
Corporate Communications 212
Sep 13, 2018: Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running 212
Mar 08, 2018: Changes to the Roche Enlarged Corporate Executive Committee 213
Sep 07, 2017: Roche ranked again the most sustainable healthcare company in the Dow Jones Sustainability Indices 214
Product News 215
Sep 18, 2018: LGC announces VALIDATE hsTnT kit for easier linearity and calibration verification on Roche cobas analyzers 215
Jun 07, 2018: Roche to showcase new solutions to consolidate automated molecular testing, microbiology topics from industry experts at ASM Microbe 2018 216
Nov 16, 2017: Roche launches DISCOVERY Teal HRP chromogen detection kit to advance tissue-based cancer research 217
Oct 03, 2017: Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams 218
Jul 31, 2017: Roche to showcase power of connected lab at AACC 2017 Clinical Lab Expo 219
May 08, 2017: Roche launches AVENIO ctDNA Analysis Kits for Oncology Research 220
Apr 12, 2017: Roche launches antibody test to aid in diagnosis of challenging prostate cancer cases 221
Other Significant Developments 222
Apr 26, 2018: Roche reports a strong start in 2018 222
Mar 02, 2018: Roche achieves two major milestones in the evolution of decision support platform 224
Feb 21, 2018: Organ-on-a-chip startup partners with Roche and Takeda 225
Jul 26, 2017: Accenture To Transform Diabetic Patient Care Using Data-driven Analytics Platform 226
May 19, 2017: med fusion Launches an EGFR Liquid Biopsy Service Based on Roche EGFR Mutation Test 227
Appendix 228
Methodology 228
About GlobalData 228
Contact Us 228
Disclaimer 228

List of Tables
F. Hoffmann-La Roche Ltd, Medical Equipment, Key Facts, 2017 2
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 11
F. Hoffmann-La Roche Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 12
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 13
F. Hoffmann-La Roche Ltd, Deals By Market, 2012 to YTD 2018 14
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 15
Roche Latvija to Acquire Distribution Business from Medilink 25
Roche Diagnostics to Acquire Tissue Dissection Technology from AvanSci Bio 26
Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 27
Care Innovations Raises Funds through Series B Venture Financing 28
Syapse Raises USD30 Million in Series D Financing 29
Viewics Raises Additional USD10.5 Million in Series B Venture Financing 31
Omicia Raises USD23 Million in Series B Financing Round 32
Cota Raises Funds through Venture Financing 33
Purigen Biosystems Raises USD18.2 Million in Series A Financing 34
Flatiron Health Raises USD175 Million in Series C Financing 35
mySugr Raises USD4.8 Million in Venture Financing 37
Curetis Raises USD18 Million in Extended Series B Venture Financing 38
GeneWeave Biosciences Raises USD12 Million in Series B Venture Financing 40
Flatiron Health Raises US$130 Million In Series B Financing 41
Curetis Raises US$16.3 Million In Series B Financing 43
MacuLogix Raises US$3.6 Million In Series A Financing 45
Flatiron Health Raises US$8 Million In Series A Financing 46
NexDx Raises US$5.5 Million In Series B Financing 48
Foundation Medicine Secures USD42.5 Million In Series B Financing 49
GeneWeave Raises US$12 Million In Series A Financing Round 51
GeneWeave Biosciences Raises USD12 Million in Venrture Financing 52
Aria Diagnostics Secures US$52.7 Million In Series C Venture Financing 53
Ariosa Diagnostics Secures USD52.7 Million in Series C Funding Round 54
Genentech Enters into Licensing Agreement with Vital Art and Science 55
Roche Enters into Licensing Agreement with Becton Dickinson 56
Ariosa Diagnostics Enters into Licensing Agreement with Labs 57
Foundation Medicine Enters into Licensing Agreement with WuXi PharmaTech 58
Roche Enters Into Licensing Agreement With Sysmex Inostics For emPCR Patent Portfolio 59
Thermo Fisher Scientific Extends Licensing Agreement With Roche For Procalcitonin Test 60
Ventana Medical Systems Enters Into Licensing Agreement With Biocare Medical 61
Ventana Medical Enters Into Licensing Agreement With German Cancer Research Center And University Hospital Heidelberg For BRAF V600E 62
Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker 63
NexDx Enters Into Licensing Agreement With University of California For Epigenetic Biomarkers 64
Roche Enters Into Licensing Agreement With Life Technologies For PCR Technology 65
Ventana Medical Systems Enters Into Licensing Agreement With Cell Signaling Technology 66
Roche Enters into Development Agreement with Novo Nordisk 67
Roche Enters into Partnership Agreement with Care Innovations 68
Five Prime Therapeutics Enters into Partnership with Roche 69
Foundation Medicine Enters into Partnership with Merck 70
Foundation Medicine, Roche and DIAN Diagnostics Enter into Partnership 71
Emulate Enters into Agreement with Roche 72
BioPorto Enters into Distribution Agreement with Roche Diagnostics 73
Syapse Enters into Agreement with Roche 74
Roche Enters into Partnership with GE Healthcare 75
Inotrem Enters into Research Agreement with Roche Diagnostics 76
Mimetas and Roche Jointly Develops Gut-On-A-Chip Technology 77
Roche Enters into Agreement with Accenture 78
Senseonics Holdings Enters into Agreement with TypeZero and Roche Diabetes 79
Loxo Oncology Enters into Agreement with Ventana Medical Systems 80
Roche Diabetes Care Enters into Agreement with Medtronic 81
Good Start Genetics Enters into Marketing Agreement with Roche Diagnostics 82
Berkeley Lights Enters into Agreement with F. Hoffmann-La Roche 83
Roche Enters into Agreement with BARDA 84
Horizon Discovery Group Enters into Co-Development Agreement with Ventana Medical Systems 85
Foundation Medicine Enters into Agreement with AstraZeneca 86
Senseonics Amends its Distribution Agreement with F. Hoffmann-La Roche 87
Flatiron Health Partners with Amgen 88
Flatiron Health Partners with Celgene 89
Cellnovo Enters into Agreement with Roche Diagnostics 90
Blueprint Medicines Enters into Co-Development Agreement with Ventana Medical Systems 91
Foundation Medicine Enters into Agreement with Mirati Therapeutics 92
IMS Health Enters into Agreement with Foundation Medicine 93
Halozyme Therapeutics Enters into Co-Development Agreement with Ventana Medical Systems for Cancer Treatment 94
Varian Medical Systems Enters into Co-Development Agreement with Flatiron Health 95
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 96
Molecular Devices Enters into Co-Development Agreement with Roche Diagnostics 97
Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 98
AstraZeneca Enters into Co-Development Agreement with Roche 99
Advanced Biological Labs Extends Co-Promotion Agreement with Roche Diagnostics 100
Bioprocessing Tech Institute Enters Into Agreement with Roche to Develop Cancer Therapeutics 101
Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 102
AUT University Forms Joint Venture with Roche Diagnostics 103
Ventana Medical Enters into Co-Development Agreement with MedImmune 104
Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 105
Foundation Medicine Extends Co-Development Agreement With Clovis Oncology 106
Ventana Extends Co-Development Agreement With Bayer Pharma 107
Ventana Medical Systems Enters Into Co-Development Agreement With Incyte For Companion Diagnostic Tests 108
Ventana Medical Systems Enters Into Agreement With Boehringer Ingelheim For Companion Diagnostic Tests 109
Ariosa Diagnostics Enters Into Agreement With Fleury For Harmony Prenatal Test 110
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 111
Advanced Biological Labs And Roche Diagnostics Enter Into Agreement To Promote Sequencing, Genotyping And Drug Resistance Products 112
Ascendis Pharma Enters Into Collaboration Agreement with Genentech 113
Ventana Medical Systems And TGen Enter Into Agreement To Develop Cancer Diagnostic Markers 114
Ventana Medical And Barco Enter Into Agreement For Digital Pathology Imaging Platform 115
Foundation Medicine Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 116
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 117
Roche Enters Into Co-Development Agreement With BioLamina For Cell Culture Systems 118
Ariosa Diagnostics Enters Into Distribution Agreement With The Doctors Laboratory For Harmony Prenatal Test 119
Epizyme, Eisai And Roche Enter Into Co-Development Agreement For Companion Diagnostic Test 120
Roche Enters Into Co-Development Agreement With Precision System Science For PCR Instrument 121
NCM USA Enters Into Co-Development Agreement With Genentech For Clinical Imaging Agents 122
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 123
Genia Technologies Enters Into Co-Development Agreement With Columbia University And Harvard University 124
Foundation Medicine Enters Into Co-Development Agreement With Clovis Oncology 125
Foundation Medicine Extends Co-Development Agreement With Novartis 126
Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 127
Sysmex Extends Distribution Agreement With Roche 128
Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems 129
Roche Enters Into Co-Development Agreement With Technoclone 131
Ventana Medical Systems Enters Into Co-Development Agreement With Bayer Pharma 132
Ventana Medical Systems Enters Into Co-Development Agreement With Pfizer 133
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 134
AEterna Zentaris Enters Into Co-Development Agreement With Ventana Medical Systems 135
Syndax Pharma Enters Into Co-Development Agreement With Ventana Medical Systems 136
Abcam Enters into Licensing Agreement with Roche 137
Sonic Healthcare Enters into Licensing Agreement with Ariosa Diagnostics 138
Roche Enters into Licensing Agreement with Dalcor Pharma 139
Ignyta Prices Public Offering of Shares for USD160 Million 140
Senseonics Holdings Prices Private Placement of Shares for USD41 Million 142
Foundation Medicine Raises USD250 Million in Private Placement of Shares 144
Ariosa Diagnostics Withdraws IPO 145
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 146
Foundation Medicine Completes IPO Of Shares For US$122 Million 147
Roche Raises USD750 Million in Public Offering of 3.25% Bonds Due 2023 149
Roche Raises USD650 Million in Public Offering of 3.625% Bonds Due 2028 150
Roche Prices Public Offering of Bonds Due 2020 for USD600 Million 151
Roche Prices Public Offering of 0.875% Bonds Due 2025 for USD1.14 Billion 152
Roche Plans to Raise USD850 Million in Public Offering of Notes 153
Roche Plans to Raise USD500 Million in Public Offering of Bonds 154
Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2021 155
Roche Plans to Raise USD1.5 Billion in Public Offering of Bonds 156
Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2024 157
Roche Plans to Raise USD300 Million in Public Offering of Bonds 158
Roche Rumored To Sell Its Diabetes Device Unit 159
SynenTec To Acquire Cellavista Systems Business From Roche 160
Roche to Acquire Remaining Stake in Foundation Medicine for USD2.4 Billion 161
Roche Acquires Flatiron Health for USD1.9 Billion 162
Roche Acquires Ignyta for USD1.7 Billion 163
Roche Acquires mySugr for USD73.1 Million 165
Roche Acquires ForSight VISION4 from ForSight Labs 166
Roche Acquires GeneWEAVE BioSciences for USD350 Million 167
Roche Acquires CAPP Medical 168
Roche Acquires Signature Diagnostics 169
Roche Acquires Ariosa Diagnostics 170
Roche Acquires Bina Technologies 171
F. Hoffmann-La Roche Completes Acquisition of Iquum for USD450 Million 172
Roche Diagnostics Acquires Genia for up to USD350 Million 173
Flatiron Health To Acquire Altos Solutions, Electronic Medical Records Company 174
Fluidigm Completes Acquisition Of DVS Sciences For US$207.5 Million 175
Roche Rumored to Acquire BioMarin Pharma for USD13.5 Billion 177
Roche Acquires Constitution Medical For US$220 Million 178
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 179
Roche Completes Acquisition Of Verum Diagnostica For US$15 Million 181
F. Hoffmann-La Roche Ltd, Key Competitors 182
F. Hoffmann-La Roche Ltd, Key Employees 183
F. Hoffmann-La Roche Ltd, Subsidiaries 184

List of Figures
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 11
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 12
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 13
F. Hoffmann-La Roche Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 14

★海外企業調査レポート[F. Hoffmann-La Roche Ltd (ROG)：医療機器：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Parsons Corp (PSN)：企業の財務・戦略的SWOT分析
    Parsons Corp (PSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • HanAll Biopharma Co Ltd (009420)：企業の財務・戦略的SWOT分析
    Summary HanAll Biopharma Co Ltd (HanAll), formerly HanAll Pharmaceutical Co Ltd, is a developer of generic and specialty drugs for treatment of diseases related to digestive, endocrine, musculoskeletal and urinary system. The company’s pipeline products include HL036, a drug being developed for trea …
  • Varian Medical Systems Inc (VAR)：医療機器：M&Aディール及び事業提携情報
    Summary Varian Medical Systems Inc (VMS) designs, manufactures and sells medical devices and software for the treatment of cancer and other medical conditions through radiotherapy, proton therapy, stereotactic radiosurgery, stereotactic body radiotherapy, and brachytherapy. The company’s major produ …
  • New Jersey Resources Corp (NJR)：企業の財務・戦略的SWOT分析
    New Jersey Resources Corp (NJR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • NanoString Technologies Inc (NSTG)：製薬・医療：M&Aディール及び事業提携情報
    Summary NanoString Technologies Inc (NanoString) is a developer of life science tools for translational research and molecular diagnostics. The company's products include sprint profiler, Dx analysis system with flex, nCounter MAX analysis system, protein assays, solid tumor assays, gene fusion pane …
  • M3 Biotechnology Inc-製薬・医療分野：企業M&A・提携分析
    Summary M3 Biotechnology Inc (M3 Biotech) is a therapeutics company that concentrates on novel platform of pharmaceuticals that modifies growth-factor systems. The company provides therapies primarily for the treatment of neurodegenerative diseases. It develops small molecule modulators with a conce …
  • Himatsingka Seide Ltd：企業の戦略・SWOT・財務分析
    Himatsingka Seide Ltd - Strategy, SWOT and Corporate Finance Report Summary Himatsingka Seide Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Zarubezhneft：石油・ガス：M&Aディール及び事業提携情報
    Summary Zarubezhneft is an oil and gas company that explores and develops oil and gas properties. The company constructs, operates and designs oil refineries, tank farms and pipeline systems for storage, transportation and marketing operations. Its services include engineering, design and account ev …
  • 4P-Pharma SAS：製薬・医療：M&Aディール及び事業提携情報
    Summary 4P-Pharma SAS (4P-Pharma) is a drug development company that offers drug pipeline for cancer and inflammatory diseases. The company’s pipeline product portfolio includes new chemical entities, biologics, added value generics and fixed dose combinations. Its pipeline candidates targets therap …
  • Owens & Minor Inc (OMI)：企業の財務・戦略的SWOT分析
    Owens & Minor Inc (OMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Actinogen Medical Ltd (ACW)：企業の財務・戦略的SWOT分析
    Summary Actinogen Medical Ltd (Actinogen), formerly Actinogen Ltd is a biotechnology company that develops novel treatments for alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases. The company’s xanamem is a novel drug under development for …
  • United States Postal Service：企業の戦略的SWOT分析
    United States Postal Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Advanced Proteome Therapeutics Corp (APC)：企業の財務・戦略的SWOT分析
    Advanced Proteome Therapeutics Corp (APC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Commerzbank AG：戦略・SWOT・企業財務分析
    Commerzbank AG - Strategy, SWOT and Corporate Finance Report Summary Commerzbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • XState Resources Ltd (XST)：企業の財務・戦略的SWOT分析
    Summary XState Resources Ltd (XState Resources) is an oil and gas exploration and development company. The company’s business activities include acquisition, exploration, production and development of oil and gas assets. It holds interest in producing gas wells and associated land leases and product …
  • Tokyo Tatemono Co., Ltd：戦略・SWOT・企業財務分析
    Tokyo Tatemono Co., Ltd - Strategy, SWOT and Corporate Finance Report Summary Tokyo Tatemono Co., Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Petrolympic Ltd (PCQ)：企業の財務・戦略的SWOT分析
    Summary Petrolympic Ltd (Petrolympic) is an oil and gas exploration and development company that acquires, explores and develops light crude oil and natural gas in North America. The company holds interests in conventional natural gas and light oil projects in Gaspe Peninsula of Quebec. It holds int …
  • Novelis Inc：企業の戦略・SWOT・財務分析
    Novelis Inc - Strategy, SWOT and Corporate Finance Report Summary Novelis Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Transgenomic Inc (TBIO)-医療機器分野：企業M&A・提携分析
    Summary Transgenomic Inc (Transgenomic) is a developer and provider of diagnostic tools and services. The company’s products include ICEme Kits, and genetic assays and platforms. It offers genetic assays and platforms such as PCR reagents, chromatography, genetic analysis kits, hanabi cytogenetic sy …
  • Achelios Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Achelios Therapeutics Inc (Achelios) is a pharmaceutical company that develops therapeutics for the treatment of pain and inflammation by topically delivered medications. The company’s lead products include Topofen, a product for the indication of acute migraine, prophylactic migraine, osteo …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆